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Abstract
Background: Annona muricata Linn which comes from Annonaceae family possesses many therapeutic benefits as
reported in previous studies and to no surprise, it has been used in many cultures to treat various ailments including
headaches, insomnia, and rheumatism to even treating cancer. However, Annona muricata Linn obtained from
different cultivation area does not necessarily offer the same therapeutic effects towards breast cancer (in regards to its
bioactive compound production). In this study, anti-proliferative and anti-cancer effects of Annona muricata crude
extract (AMCE) on breast cancer cell lines were evaluated.
Methods: A screening of nineteen samples of Annona muricata from different location was determined by MTT assay
on breast cancer cell lines (MCF-7, MDA-MB-231, and 4 T1) which revealed a varied potency (IC50) amongst them. Then,
based on the IC50 profile from the anti-proliferative assay, further downward assays such as cell cycle analysis, Annexin
V/FITC, AO/PI, migration, invasion, and wound healing assay were performed only with the most potent leaf aqueous
extract (B1 AMCE) on 4 T1 breast cancer cell line to investigate its anti-cancer effect. Then, the in vivo anti-cancer study
was conducted where mice were fed with extract after inducing the tumor. At the end of the experiment, histopathology
of tumor section, tumor nitric oxide level, tumor malondialdehyde level, clonogenic assay, T cell immunophenotyping,
and proteome profiler analysis were performed.
Results: Annona muricata crude extract samples exhibited different level of cytotoxicity toward breast cancer cell lines.
The selected B1 AMCE reduced the tumor’s size and weight, showed anti-metastatic features, and induced apoptosis in
vitro and in vivo of the 4 T1 cells. Furthermore, it decreased the level of nitric oxide and malondialdehyde in tumor
while also increased the level of white blood cell, T-cell, and natural killer cell population.
Conclusion: The results suggest that, B1 AMCE is a promising candidate for cancer treatment especially in breast
cancer and deserves further research as an alternative to conventional drugs while also stressed out the selection of
soursop sample which plays a significant role in determining its potential therapeutic effect on cancer.
Keywords: Annona muricata Linn, Breast cancer cell line, Potency, Leaf aqueous extract, Apoptosis, Anti-metastatic,
Immune systems, Inflammation
Abbreviations: AMCE, Annona muricata crude extract; AO/PI, Acridine orange/propidium iodide;
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Background
Breast cancer is one of the leading cancer affecting
women as over 1 million women worldwide are diag-
nosed with this disease each year [1]. Despite the current
drugs present that manage to suppress the tumor
growth, there is an urgent need to explore alternative
strategies to overcome several limitations in treating
breast cancer including the metastasis of cancerous cells
which is the leading cause of mortality and morbidity,
increasing the sensitivity of immune system response,
and reducing the inflammation caused by cancer. With
the advance of research to date, many medicinal plants
have been subjected to scientific scrutiny where their
secondary metabolites/bioactive compounds are discov-
ered to have the anticancer effect potential. Annona
muricata Linn which belongs to the Annonaceae family
has been used in traditional medicine to treat various
ailments including fever, rheumatism, cancer, and also as
sedative, insecticide, and immunosuppressive activity [2].
Intensive research on the chemical composition of the
leaves [3] and seeds [4] lead to the finding of acetogenin
compounds which explains the therapeutic effects it pos-
sessed. Acetogenin (ACG) is characterized by its un-
branched C32 or C34 fatty acid with a γ-lactone at the
end of the cytoskeleton [5]. This molecular structure is a
very potent compound against cancer as it deprives the
highly energy demanding cancer cells from adenosine
triphosphate (ATP) supply via the disruption of mito-
chondrial electron transport system, hence resulting in
apoptosis [6, 7]. The production of secondary metabo-
lites is actually a response by plants to cope with the
harsh or ever changing environments. It has been re-
ported that plant of similar species collected from differ-
ent locations has a varied level of secondary metabolites
among them [8] which indicates that the production of
the bioactive compounds in the soursop plant could also
vary thus, affecting its potency against cancer cell. As
that notion has not yet been tested, therefore, the pur-
pose of this study was to screen the cytotoxicity level of
the Annona muricata crude extract (AMCE) against the
breast cancer cell lines (MCF-7, MDA-MB-231, and
4 T1) as well as to further evaluate the anticancer effect
possessed by the selected (most potent) AMCE on 4 T1
cancer in vitro and in vivo.
Methods
Preparation of Annona muricata Crude Extract (AMCE)
Samples of Annona muricata leaves were obtained from
the Annona muricata cultivars in Johor, Melaka, Negeri
Sembilan, Selangor, Perak, and Perlis in the months of
September to November 2014. The plant was identified
and deposited with a voucher number by Science Officer
Lim Chung Lu from the Forestry Division, Forest Re-
search Institute Malaysia. Details of the sampling sites
and voucher number of each sample are shown in
Additional file 1: Table S1. All of the 19 samples of old
mature Annona muricata leaves were air-dried for a
week before being ground to a powder using a grind
mill. Later, about 10 g of each powdered samples were
transferred into a Schott bottle containing 200 mL of
cold sterile distilled water. The samples were incubated
for 3 days with frequent agitation using an orbital shaker
at room temperature. The mixture was then, filtered to
discard any solid material/marc. Finally, the filtrate ex-
tract was dried using the freeze dryer/ lyophilizer ma-
chine to give the end product (AMCE).
Cell culture
The cell lines, MCF-7, MDA-MB-231, 4 T1 and MCF-
10A were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). The MCF-7
and 4 T1 cells were maintained in RPMI 1640 medium
while MDA-MB-231 cell was maintained in DMEM
medium. Both media were supplemented with 10 % Fetal
Bovine Serum (FBS) and 1 % Penicillin/Streptomycin.
MCF-10A on the other hand, was maintained in DMEM-
F12 medium supplemented with hydrocortisone (0.5 μg/
mL), insulin (10 μg/mL), hEGF (20 ng/mL) and 10 % FBS.
The cells were grown in a humidified incubator at 37 °C
in the presence of 5 % CO2. The cell was passaged upon
reaching 70 % confluency.
MTT assay
The proliferation of the cells or cell viability was assessed
by the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazo-
lium bromide (MTT) dye reduction as described by
Zhi-Dong et al [9]. The cytotoxic potential of the crude
extract samples could be determined from this assay based
on the IC50 generated. A hundred microliter of cells at a
concentration of 0.8 × 105 cells/well were placed into a
96-well plate and maintained in the respective medium
(RPMI/DMEM) for 24 h. The following day, Annona mur-
icata crude extract (AMCE) was added to the wells and
then, incubated for 72 h. MTT solutions (5 mg/ml) was
added at a volume of 20 μL into each wells and incubated
for 3 h. Later, the solutions were removed from wells and
100 μL of DMSO were added to solubilize the formazan
crystals. Finally, the plate was read using an ELISA plate
reader at a wavelength of 570 nm (Bio-tek Instruments,
USA).
Annexin V/FITC assay
The Annexin V/FITC assay was performed using Annexin
V Kit (BD Pharmigen, USA) in order to analyse the poten-
tial of B1 AMCE in causing apoptosis. The cells were
seeded in a 6-well plate at a concentration of 2.4 × 105
cells/mL and incubated overnight. On the next day, the
seeded cells were treated with the IC50 value of Annona
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muricata crude extract (AMCE) and incubated for 48 and
72 h. The cells were harvested according to the incubation
time point and the resulting pellets were resuspended in
the binding buffer provided. Five microliter of FITC
Annexin V and 5 uL of PI were added to stain the cells
suspension and allowed to stand in a dark place at room
temperature for 15 min. Afterwards, the stained cells were
analysed by flow cytometry machine (Becton Dickinson,
USA).
Acridine Orange/ Propidium Iodide assay (AO/PI)
Cell viability/apoptosis of the 4 T1 cells was analysed
based on the AO/PI dual staining of live/dead nucleated
cells. The AO/PI assay was carried out according to the
protocol described by Salim et al. [10] with a slight modifi-
cation. Cells were seeded in a 6 well-plate at a concentra-
tion of 2.4 × 105 cells/mL and incubated overnight before
treating with the IC50 value of Annona muricata crude
extract (AMCE) the following day. The cells were incu-
bated for another 72 h. Afterwards, the cells were har-
vested and the resulted pellets were resuspended in
200 μL PBS. Six microliter of the suspended cells was then
stained with 4 μL AO/PI and the mixture were loaded
onto a glass slide. The images were captured with a fluor-
escence microscope equipped with Nikon camera.
Cell cycle assay
To further examine the effects of B1 AMCE on the induc-
tion of apoptosis, the effects on the cell cycle was tested.
The cell cycle assay was carried out using CycleTEST
PLUS DNA Reagent Kit (BD Pharmigen, USA). The cells
were seeded at a concentration of 2.4 × 105 cells/mL in a
6 well-plate and incubated overnight. The next day, the
seeded cells were treated with IC50 of Annona muricata
crude extract (AMCE) and incubated for 72 h. After tryp-
sinization, cells were collected and a volume of 250 μL of
solution A (trypsin buffer) was added. After 10 min of in-
cubation at room temperature, 200 μL of solution B (tryp-
sin inhibitor and RNase buffer) were added and the cell
suspension was mixed gently. A further 10 min of incuba-
tion time at room temperature were required before a
200 μL of cold solution C (propidium iodide stain solu-
tion) were added to stain the cells. The mixture solutions
were incubated for another 10 min in the dark on ice
before analysed by flow cytometer machine (Becton
Dickinson, USA).
Migration/Invasion assay
This assay was attempted based on the predicament of
the 4 T1 cells are able to migrate/invade with the pres-
ence of stimulants. It was conducted based on the proto-
col outlined by Chen [11]. Prior to the experiment, a
70 % confluent 4 T1 cells were serum starved for 24 h
before being seeded at a density of 2 × 105 cells/mL in
the insert chamber coated with solidified Matrigel (BD
Biosciences) for the invasion assay whereas for the mi-
gration assay, the chamber was not coated by the Matri-
gel basement membrane. In the lower compartment of
the chamber, 2 mL of RPMI medium supplemented with
10 % FBS and the desired concentration of Annona mur-
icata crude extract was added. The inserts were incu-
bated in a 37 °C CO2 incubator for 24 h. The inserts
were removed afterwards and the inner side of the in-
serts were swabbed to remove the non-/invaded cells.
The outer side of the inserts bearing the migrated/in-
vaded cells were then fixed in methanol for 30 min be-
fore being stained with 0.5 % of crystal violet. The
images appeared on the membranes were later captured
with an inverted microscope equipped with a camera
(Nikon, Japan).
Wound healing assay
This assay was done using the method outlined by Liang
et al. [12]. A concentration of 3.5 × 105 4 T1 cells were
seeded in a 6-well plate and incubated overnight. The next
day, a straight wound line was drawn across the 100 %
confluent attached cell layer with pipette tips. The floating
cells were removed with PBS and replaced with new fresh
RPMI medium. Annona muricata crude extract (AMCE)
was added to the wells and images of the closure of the
wound were recorded at time point 0, 3, 6, 9, 12, and 24 h
using the inverted microscope equipped with a camera
(Nikon, Japan).
Animal and diet
Six to eight-week-old female BALB/c mice were used for
in vivo experiments and were obtained from UPM Ani-
mal Resource Unit. Mice were divided into groups and
acclimatized for 7 days, fed with normal diet and water.
All methods involving the experimental use of animals
have been reviewed and approved by the Institutional
Animal Care and Utilize of Committee of the Faculty
Veterinary and Medicine, Universiti Putra Malaysia (Ref-
erence Number: UPM/IACUC/AUP/RO55/2015). All ani-
mals were fully conducted in humane and ethical care and
under the regulation of the governing body concerning
the animals.
Animal treatment
Mice were separated into 3 open-cages defining their re-
spective groups; normal, untreated, and treated where
each group bearing 7 mice per cage. Mice in the un-
treated and treated group were induced with 1 × 105
cells/mL of 4 T1 breast cancer cells via subcutaneous
(s.c) injection using a 27 gauge needle (Teruma, USA).
Mice were observed on a daily basis for about 5 days
until the tumor masses develop. Treatment with Annona
muricata crude extract (AMCE) of 20 mg/20 g mice was
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given to the treated group while the other two groups
were fed with distilled water. This treatment was con-
ducted once daily for 28 days. After 28 days of treat-
ment, the mice were euthanized and then sacrificed by
cervical dislocation. Tissue samples like tumors and vital
organs which include lung and spleen were harvested
and directly used in downward analysis. One-half of the
tumors were placed in tubes containing 10 % formalin
for fixation and histological analysis while the other half
were stored in tubes containing ‘RNAlater’ solution.
Hematoxylin and eosin histology staining of the tumors
The harvested tumors were fixed in 10 % formalin and
were embedded in paraffin before being sliced into thin
sections. Then the paraffin sections were stained with
hematoxylin and eosin (H&E) and were viewed under a
bright-field microscope (Nikon, Japan). The mitotic cells
present were counted and compared between the groups.
Lung clonogenic assay
The metastasis of 4 T1 cells to other parts from primary
tumor site was investigated by clonogenic assay. The
clonogenic assay was carried out based on DuPre et al’s
protocol [13]. Lung organ was harvested from the un-
treated and treated group of mice under sterile condition
and was chopped into smaller pieces as to avoid the
clogging of pipette. Afterwards, it was placed in the
tubes containing 5 mL PBS and 100 uL (2 mg/mL) of
collagenase type IV for 30 min at 37 °C. The solutions
were passed through a 70 mm cell strainer and recol-
lected in a new tube before centrifuging to obtain the
pellet. The cells pellets were washed with PBS twice before
being resuspended in 10 ml RPMI medium supplemented
with 10 % fetal bovine serum and 60 μM 6-thioguanine
(Fisher, USA). The cell suspension was plated in a 6-well
plate and a 1/10 serial dilution was performed to fill the
other 5 wells of the same plate. The plates were incubated
for 10 days in a 37 C incubator equipped with 5 % CO2.
Unattached cells were rinsed with PBS twice before the at-
tached cells/colonies were fixed in methanol for 1 h and
later stained with 0.5 % crystal violet for another 1 h. The
wells were washed by PBS and viewed under microscope.
Immunophenotyping assay
The effect of B1 AMCE on the level of immune cells
population from spleen was investigated by this assay.
The spleens from the mice of all groups were harvested
in a sterile condition. They were placed into a petri dish
containing PBS solution and were mashed through
70 μL cell strainer. The single cell suspension were
washed twice with ice-cold PBS and followed by the cen-
trifugation step. The splenocytes were resuspended in a
2 mL NH4Cl lysis buffer and incubated for 10 min at 4 °C.
Later, the cells were washed with PBS and centrifuged
until a clean yellow pellet obtained. The pellets were dis-
solved in PBS and CD3, CD4, CD8, AND NK1.1 dye
(Abcam, USA) were added into tubes accordingly in dark
condition and were shook at 150 rpm for 2 h. Afterwards,
1 mL of PBS was added and the tubes were centrifuged.
The resulted pellets were dissolved with 600 uL of 1 %
paraformaldehyde and stored in the dark place at 4 °C
before being analysed by flow cytometer machine (BD,
USA).
MDA antioxidant assay
The effect of B1 AMCE as antioxidant against lipid per-
oxidation in 4 T1 tumor sample was investigated on the
basis of the level of malondialdehyde (MDA). Two hun-
dred microliter of tumor sample supernatant was mixed
with 800 μL of PBS, 25 μL of butylated hydroxytoluene
(BHT), and 500 μL TCA. The mixture was vortexed and
incubated on ice for 2 h. After centrifuging at 2000 × g
for 15 min, 1 mL of supernatant was taken out and
transferred into tube containing 75 μL of 0.1 M EDTA
and 250 μL of 0.05 M TBA. The tube was boiled in
water bath for 15 min and then, left to cool at room
temperature before read by spectrophotometer at 532 nm
and 600 nm wavelengths. The result obtained was com-
pared to MDA standard curve.
Nitric oxide/Griess reagent assay
The effect of B1 AMCE on the level of nitric oxide in
4 T1 tumor was investigated using the Griess reagent
assay. It was carried out using the Griess Reagent Kit for
Nitrite Determination (Life Technologies, USA). Twenty
microliter of Griess reagent containing equal volume of
sulfanilic acid and N-1-napthylethylenediamine dihy-
drochloride was mixed with 150 μL of the nitrite-
containing sample and 130 μL of deionized water in a
microplate and incubated for 30 min at room tem-
perature. Standard curve was also prepared by diluting the
nitrite standard solution with deionized water to give a
series of concentration between 1–100 μM. In place of the
nitrite- containing sample, the standards were mixed with
the Griess reagent and incubated in a similar manner. The
absorbance of the sample and standards were read by
spectrophotometer (Beckman Coultor, USA) at 548 nm
wavelength before the nitrite concentrations correspond-
ing to the standard plot could be evaluated.
Proteomic assay
The effect of B1 AMCE on the protein level affecting
the angiogenesis process in 4 T1 tumor was investigated
using the Raybio Mouse Angiogenesis Kit (RayBiotech,
Inc.). A volume of 100 μL of 1x Blocking Buffer is added
into each well of the glass chip and incubated at room
temperature for 30 min. The Blocking Buffer were dec-
anted and aspirated before 100 μL of samples were added
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into the wells and incubated for 2 h at RT. Later, the
samples were removed and the wells were washed with
Wash Buffer I for 3 times at each 2 min interval. The
glass chip assembly was submerged into a container
containing Wash Buffer I and shook gently for 10 min
and this step was repeated with the Wash Buffer II.
The wash buffer was decanted before 70 μL of 1X
Biotin-conjugated Anti-cytokines were added into each
wells and incubated with gentle rocking for 2 h at RT.
After washing with Wash Buffer I and followed by
Wash Buffer II, a 70 μL of 1X Streptavidin-Fluor were
added to each well and incubated in a dark room for
another 2 h in a similar manner. The washing steps
were followed after removing the streptavidin-fluor
from the glass chip. Later, the glass chip was removed
from its tube assembly and rinsed with deionized water. A
dry glass chip was sent immediately to scanning with laser
scanner (Innopsys‘InnoScan) at excitation frequency of
532 nm.
Statistical analysis
All data were expressed as the means ± standard error of
mean (S.E.M.). The analysis was performed with one-
way analysis of variance (ANOVA) and the group means
were compared by Duncan test. Values of p < 0.05 were
considered as statistically significant.
Results
Anti-proliferative effect of Annona muricata crude extract
(AMCE) on MCF-7, MDA-MB-231, and 4 T1 cells
Cell viability was determined by comparing to the sur-
vival of cells in the untreated (negative control) cultures,
which was normalised to 100 %. The IC50 results for the
anti-proliferative effect of the 19 samples of AMCE on
three different breast cancer cell lines; MCF 7, MDA-
MB231, and 4 T1 were shown in Table 1. The cells were
treated with 2-fold serial dilutions of AMCE for 72 h. B1
sample was the most potent AMCE among others as it ex-
hibited the lowest IC50 (half-maximal inhibitory concentra-
tion) for all breast cancer cell lines (MCF 7 = 220 μg/mL;
MDA-MB231 = 350 μg/mL; 4 T1 = 250 μg/mL) as depicted
in Fig. 1. Figure 1 also showed the IC50 of B1 AMCE on
the positive control cell line, MCF-10A was considerably
higher than the three cancer cell lines (1000 μg/mL). On
the other hand, A2 and R2 samples were the least potent
as both showed weak activity in inhibiting the prolifera-
tion of cancer cells as they have higher IC50 compared to
the other ACME samples.
B1 AMCE sample induced apoptosis in 4 T1 breast
cancer cells
Figures 2 and 3 showed the results of Annexin V FITC
of 4 T1 cells after treating with the IC50 of B1 AMCE at
two different time intervals; 48 h and 72 h respectively.
The lower left quadrant of both histograms shows the
population of the viable cells while the lower right quad-
rant represents the population of early apoptotic cells.
The upper right quadrant represents the non-viable and
late apoptotic/necrotic cells. There is a pattern of cell
population shifting from viable cells to early apoptotic to
late apoptosis/necrosis in both time-points. Based on
Table 2, at the 48-hour time interval, the early apoptotic
cell population increased gradually from 1.24 % ± 0.06 %
in the control group to 26.9 % ± 1.18 % in IC50 of the
treatment group whereas at 72-hour time interval, the
cells increased from 2.39 % ± 0.09 % in the control group
to 35.13 % ± 1.19 % in the treatment group. There was
also an increase in population of late apoptotic cells
from 1.89 % ± 0.03 % and 1.33 % ± 0.09 % in the control
group to 10 % ± 0.08 % and 14.25 % ± 0.62 % in the B1
AMCE treatment group of the 48-h and 72-h time-point
respectively. The difference of cell population percentage
between 48 and 72-h time interval indicates that B1
AMCE was cytotoxic and induced apoptosis in time-
dependant manner. These results (48 and 72 h treat-
ment) coupled with the positive results shown in the in
vivo tests (later will be discussed) that involved daily
Table 1 The mean values of IC50 of all AMCE samples from MTT
assay in MCF 7, MDA-MB-231, and 4 T1 cells
Sample Breast cancer cell line
MCF 7 MDA 4 T1
J1 302.33 ± 1.45b 347.67 ± 1.45a 321.67 ± 7.27c
M1 348.33 ± 1.67b 360 ± 5.77a 312.33 ± 1.45e
M2 547.33 ± 3.93f 519.67 ± 2.91f 501 ± 3.05h
M3 349.33 ± 2.96d 496.67 ± 3.33e 450.67 ± 8.29e
M4 500.67 ± 6.36d 600 ± 1.16g 450 ± 10.41g
N1 251.33 ± 0.67d 353.67 ± 5.93a 449.67 ± 1.45b
N2 648.33 ± 4.41g 601.5 ± 4.44g 535 ± 7.64j
N3 550 ± 8.66h 601.67 ± 0.88g 599.33 ± 7.88h
B1 221.67 ± 1.67a 350 ± 5.77a 251.67 ± 6.01a
B2 249.33 ± 4.7d 379 ± 3.06b 449.33 ± 7.88b
B3 330 ± 1.73c 348.33 ± 4.41a 400 ± 8.74d
A1 349.33 ± 7.22e 461.33 ± 9.14d 472.67 ± 5.36e
A2 701.67 ± 4.41i 731.67 ± 0.88j 646.33 ± 1.86k
A3 453.67 ± 1.86d 431.67 ± 16.91c 443 ± 3.51f
A4 302 ± 1.53c 360.67 ± 5.81a 400.67 ± 2.96c
R1 702.67 ± 1.45f 670.67 ± 0.67i 501 ± 6.66k
R2 799.67 ± 0.88h 769.33 ± 7.06k 605 ± 5l
R3 650 ± 5.77f 654.33 ± 6.36hi 500 ± 7.64j
R4 620 ± 2.89d 648 ± 1.73h 452.67 ± 6.23i
Each data was expressed as mean ± standard error of mean (S.E.M) of triplicate
determinations. Mean values with different superscripts in the same column
are significantly different p < 0.05
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treatment for 28 days lead to the assumption that this
crude extract is a potential candidate for treating breast
cancer in human, as it can modulate its therapeutic ef-
fect continuously with no sign of resistance hence, ef-
fectively inhibit the growth of cancer cell in vitro and in
vivo. Based on Fig. 4, the untreated 4 T1 cells were
marked with distinct green intact nuclear structure
colour which showed normal structure without promin-
ent apoptosis and necrosis. On the other hand, the
treated 4 T1 cells were consisted of cells population of
bright green and orange-reddish colour as a result of the
intercalation of AO and PI within the fragmented DNA,
which represented the incidence of early apoptosis and
late apoptosis respectively. To further study AMCE po-
tential in inducing apoptosis, the cell cycle analysis was
carried out using flow cytometric methods. Based on
Fig. 5 and Table 3, after treatment with B1 AMCE
(250 μg/mL) for 72 h, the percentage of cell population
in the sub G0/G1 phase was significantly higher than in
the control group (4.37 % ± 0.20 % versus 18.02 % ± 2.21
in the control group). This result suggested that B1
AMCE arrested the cell cycle at the sub G0/G1 phase
and induced apoptosis in vitro. On the other hand, H&E
images of the sectioned tumors as shown in Fig. 6 indi-
cated a decrease in the number of mitotic cells (black
circles) in the B1 AMCE-treated tumor compared to the
control tumor. The low mitotic number means the de-
cline of the number of actively dividing cells, thus, in-
hibit the cancer cells from sustaining themselves.
Anti-metastatic potential of B1 AMCE sample on 4 T1 cells
In assessing the anti-metastatic abilities of B1 AMCE, in
vivo clonogenic assay and in vitro assays like wound
healing analysis, migration and invasion were carried
Fig. 1 Representative MTT assay showing the cytotoxicity activity of B1 AMCE in three different types of cancer cells; MCF 7, MDA-MB-231, and
4 T1 and normal breast cell; MCF-10A after 72 h of incubation in vitro
Fig. 2 Histogram analysis of Annexin V/FITC in 4 T1 cells after being treated with IC50 concentration of Annona muricata crude extract (AMCE)
after 48 h
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out. In Fig. 7, it can be seen that there was a decrement
in the percentage of wound closure in the B1 AMCE-
treated 4 T1 cells, 43.9 % when compared to the control
group, 100 %. In the migration assay, only 31 % of can-
cer cells managed to migrate through the transwell
membrane when treated with B1 AMCE, as shown in
Fig. 8b. This low percentage of migration rate in the
treated cells compared to the control cells (100 %) indi-
cated the potential of B1 AMCE to inhibit cancer cells
migration. From the Matrigel invasion assay as shown in
Fig. 9a, the ability of 4 T1 cells to invade a basement
membrane was significantly compromised in the B1
AMCE-treated 4 T1 cells relative to the control cells.
Quantifying this result, it was shown that treatment with
B1 AMCE only allows 44 % cells to invade the basement
membrane relative to the control cells (Fig. 9b). These
results indicated that B1 AMCE significantly inhibited
the migration and invasion of 4 T1 breast cancer cells in
vitro. The metastasis of 4 T1 cancer cells in mice at the
distant organ such as lung was determined via clono-
genic assay as depicted in Fig. 10a. In Fig. 10b, the num-
ber of colonies formed in the lung was reduced
significantly in the B1 AMCE treatment group (15 ±
0.82) compared to the control group (67 ± 2.05). In
Fig. 11, several angiogenesis-related proteins were tested
by proteome profiler in determining the proteins level of
the B1 AMCE-treated group in relative to the control/un-
treated group (fold change). In comparison to the control
group, the level of proteins such as Eotaxin, Fas Ligand,
IGF-II, IL-1β, IL-13, Leptin, TNF-α, and TIMP-1 were de-
creased in B1 AMCE-treated group (0.83 ± 0.01, 0.68 ±
0.03, 0.86 ± 0.01, 0.76 ± 0.04, 0.63 ± 0.03, 0.70 ± 0.02,
0.83 ± 0.01, 0.990 ± 0.04) respectively. However, the level
of proteins likes IFN-gamma and MIG were increased
(1.32 ± 0.39 and 1.17 ± 0.03) respectively.
B1 AMCE sample impeded the growth of tumor in vivo
The therapeutic effects of the B1 AMCE treatment in
mice bearing the 4 T1-induced tumors were assessed
after 28 days of treatment. Based on Fig. 12, the size of
tumor in the control group are approximately similar to
the B1 AMCE-treated group. However, the weight and
volume of the tumor were different when compared be-
tween these two groups as shown in Figs. 13 and 14 re-
spectively. In Fig. 13, the tumor weight decreased from
1.45 ± 0.06 g in the untreated group to 1.2 ± 0.09 g in the
B1 AMCE-treated group. The mean tumor volume of
the group treated with B1 AMCE was 271.7 ± 14.24 mm
Fig. 3 Histogram analysis of Annexin V/FITC in 4 T1 cells after being treated with IC50 concentration of Annona muricata crude extract (AMCE)
after 72 h
Table 2 Flow cytometric analysis of phosphatidylserine externalization on 4 T1 cells after 48 and 72 h of treatment
Treatment group Percentage of cells (%)
Viable Early apoptosis Late apoptosis Dead
48 h Control 95.98 ± 0.15 1.24 ± 0.06 1.89 ± 0.03 0.89 ± 0.08
B1 AMCE 61.48 ± 1.13*a 26.9 ± 1.18*a 10.01 ± 0.08*a 1.61 ± 0.1
72 h Control 95.09 ± 0.24 2.39 ± 0.09 1.33 ± 0.09 1.18 ± 0.17
B1 AMCE 49.39 ± 1.74**b 35.13 ± 1.19**b 14.25 ± 0.62**b 1.24 ± 0.14
Each data was expressed as mean ± standard error of mean (S.E.M) of triplicate determinations. *Statistical significance (p<0.05) between control and B1 AMCE-
treated group in 48-hour time-point. **Statistical significance (p<0.05) between control and B1 AMCE-treated group in 72-hour time-point. Mean values with differ-
ent subscripts in the same column are significantly different p < 0.05
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Fig. 4 Images represent the control and treated cells which were stained with acridine orange and propidium iodide (AO/PI) after 72 h. 4 T1 cells
were treated with IC50 of Annona muricata crude extract from B1 sample. Magnification: 100x
Fig. 5 Histogram analysis of the cell cycle machinery in 4 T1 cells after being treated with B1 Annona muricata crude extract (AMCE) after 72 h
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[3] which was smaller than the untreated group, 375 ±
25.98 mm [3] as depicted in Fig. 14.
B1 AMCE sample regulated several immune systems
markers in vivo and increase the level of white blood cell
Immunophenotyping of the splenocyte cell population
was carried out in order to gain the knowledge on the
effect of B1 AMCE in modulating several important im-
mune markers. In Fig. 15b, it can be seen that the sple-
nocyte population of CD4/CD3-T cell was decreased
from 25.6 % ± 0.11 % (normal group) to 17.46 % ± 0.28 %
(control/untreated) but a significant increase was observed
in the B1 AMCE-treated group (19.47 % ± 0.22 %). A simi-
lar trend was also observed in CD8/CD3-T cell population
(Fig. 15c). A drop of CD8/CD3-T cell population percent-
age level was detected in the control group (5.83 % ±
0.10 %) when compared to the normal group (12.62 % ±
0.21 %) but the level of CD8/CD3- T cell population was
elevated in the B1 AMCE-treated group (6.98 % ± 0.23 %).
In addition, the population of natural killer (NK) 1.1/
CD3+ cell was increased in the B1 AMCE-treated group
(5.73 % ± 0.16 %) compared to the control/untreated
group (4.69 % ± 0.13 %) as depicted in Fig. 16. Based on
Table 4, the total white blood cell count observed was
4.5 × 109 /L in the B1 AMCE-treated mice group which
was higher than in the control group (2.4 × 109 /L).
B1 AMCE regulated inflammation
The level of nitric oxide (NO) and malondialdehyde
(MDA) in the tumor were assessed in both the control
group and B1 AMCE-treated group. In Fig. 17, the level
of nitric oxide marked a lower level of NO in the treated
group (72.93 ± 17.12 μM/mg) compared to the control
group (123.41 ± 20.29 μM/mg). A similar pattern was
also observed in Fig. 18 where the MDA level was
decreased from 0.99 ± 0.10 nM/mg in the control/un-
treated group to 0.48 ± 0.16 nM/mg in the B1 AMCE-
treated group.
Discussion
Natural products have been the target for cancer therapy
for many years due to the medicinal values contained in
them. In this study, the cytotoxicity effect of the aqueous
leaf extract of Annona muricata Linn samples were eval-
uated on three different breast cancer cell lines; MCF-7,
MDA-MB-231, and 4 T1 by MTT assay. Consistent with
earlier findings [14], each of the soursop crude extract
exhibited the anti-cancer activity as they inhibited the
proliferation of the breast cancer cell lines as depicted in
Table 1. The IC50 values are varied among the samples
revealing the influence of the secondary metabolites
constituents composed in them. This situation could be
explained by the geographical difference of the sample
cultivation area. The geographical difference of the culti-
vated plant means that each plant are exposed to differ-
ent climate and environmental stress factors such as
humidity, temperature, and soil composition [15]. The
synthesis and accumulation of secondary plant products
are enhanced in stress environment such as water deficit
condition [16]. In harsh environment, plant adjusts their
regulation of phenylpropanoid biosynthesis pathway at
multiple levels in response to the exogenous factors. For
example, green tea cultivated in area with high tempera-
ture, long sun exposure time, and high rainfall exhibits a
higher concentration of theanine and lower concentra-
tion of leucine, isoleucine, epicatechin, and epigallocate-
chin compared to those cultivated in low temperature,
short sun exposure time, and low rainfall [17]. Previous
study had also shown that plants exposed in drought
stress produce higher level of secondary metabolites in-
dicating a crucial linkage between the environmental
factor and metabolites contents [18]. In regards to those
aspects, the cultivation area of B1 AMCE might be the
harshest compared to the other samples hence, could be
the underlying reason of its highest potency in killing
cancer cells. Based on the cytotoxicity profile obtained,
the aqueous leaf extract of soursop samples were more
selective towards MCF-7 followed by 4 T1 and MDA-
MB-231 cell line. As 4 T1 cell line was more aggressive
than the other two cell lines and also to avoid any con-
flict of interest, 4 T1 cell line was chosen to be used in
the downward assays. B1 AMCE sample which exhibited
the best IC50 profile was selected for further use to treat
the 4 T1 cells. Additionally, a successful anti-cancer
drug should incapacitate cancer cells without causing
excessive damage to normal cells thus, indicating min-
imal side effects. In this study, cell viability of normal
breast cells, MCF10A in the presence of B1 AMCE treat-
ment was determined. It appeared that B1 AMCE treat-
ment was less toxic on normal cells as it required higher
dosage to kill the cells (IC50 = 1000 μg/mL) which was
four times higher than the IC50 of B1 AMCE in 4 T1
cells, thus, suggesting the low side effect of this plant
crude extract. Flow cytometric analysis of Annexin V/
FITC at 48-h and 72-h time-point distinguished a separ-
ate population of early apoptotic, late apoptotic/necrotic
cells, and living cells as a result of the employment of
Table 3 Percentage of cells in each of the cell cycle phases
after treatment with B1 AMCE for 72 h
Control IC50(250μg/mL)
Sub G0/G1 4.37 ± 0.20a 18.02 ± 2.21b
G0/G1 45.23 ± 0.25a 43.12 ± 0.75b
S 29.98 ± 0.31a 23.48 ± 0.93b
G2 +M 20.55 ± 0.19a 15.39 ± 0.70b
Each data was expressed as mean ± standard error of mean (S.E.M) of triplicate
determinations. Mean values with different superscripts in the same row are
significantly different p < 0.05
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Fig. 6 (See legend on next page.)
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the high affinity binding of Annexin V to phosphatidyl-
serine (PS), a phospholipid component of the cell mem-
brane. The dying cells which undergo apoptosis event
experience a physiological change that causes the exter-
nalization of PS to the outer leaflet of the plasma
membrane. As depicted in Table 2, the total apoptosis
percentage (early apoptotic and late apoptotic/necrotic
cells) in the B1 sample treatment group was higher than
the untreated group. It is in accordance to the results
presented in earlier report of apoptosis induction by
soursop on colon cancer cells [19]. It is noteworthy that
the B1 sample treatment induces the apoptosis in time-
dependant manner where the apoptotic cells in 72-h
time-point was found higher than in the 48-h time-point.
(See figure on previous page.)
Fig. 6 a Histological staining of both the tumors (control and B1 AMCE-treated) with hematoxylin and eosin (H&E). b Quantification of histological
staining of the sectioned tumors of control and B1 AMCE-treated group. The dosage used in the treated group was 20 mg/20 g mice B1 Annona
muricata crude extract (B1 AMCE). The data are expressed as means ± standard error of the mean for triplicates. Significance is set at *p < 0.05; n = 7
mice per group
Fig. 7 a Representative images of the wound healing analysis of 4 T1 cell at 0 h and 24 h for control and cells treated with IC50 value of B1
Annona muricata crude extract. Magnification: 100x. b Percentage of wound closure in 4 T1 cells when a wound is introduced. The assay was
done in triplicates and the data are expressed as mean ± standard error of mean. Significance is set at *p < 0.05
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As Annexin V/FITC analysis relies on the externalization
of PS, the adoption of this AO/PI assay was purposely to
detect different cellular event or morphological changes of
the cells when treated with B1 AMCE sample. Apoptotic
features such as membrane blebbing, nucleus condensa-
tion, and DNA fragmentation were evidently showed by
AO/PI staining in the treated 4 T1 cells, thus strengthen
the potential of soursop aqueous extract in inducing apop-
tosis and inhibiting breast cancer cells [20]. Subsequently,
cell cycle analysis was also performed as the deregulation
of cell cycle is closely related with apoptosis [21]. The
regulation of cell cycle involves several checkpoint path-
ways to ensure the completion of one phase of the cell
cycle before entering into another cycle phase in order to
maintain the integrity of cell [22]. A significant increase of
cell population at the sub G0/G1 phase was observed and
shown in Table 3 which suggested the incident of cell
cycle arrest in the B1 AMCE treated group. Halting the
cell cycle progression in cancer cells eventually leads to
the cell death which befits the idea of treating the breast
cancer cells. Our data attested that B1 AMCE is capable
of suppressing the tumor growth in the 4 T1 breast cancer
in murine tumor models (after 28 days of treatment)
based on the regression of weight and volume of the
tumors, in agreement with the in vitro assays (MTT,
Annexin V/FITC, AO/PI, cell cycle analysis) results. Add-
itionally, according to the H&E staining of the tumors, the
number of actively dividing cells (i.e., mitosis) which is a
distinguished feature of cancer cells was reduced following
the treatment of tumor with B1 AMCE when compared
to the untreated control tumor. In order to consider that
B1 AMCE as a potential candidate for antitumor drug, it
is imperative that it possesses the capacity, by any mean,
to inhibit the breast cancer cell from metastasize since the
progression of tumor is not only dependent upon its pro-
liferative rate. Metastasis which involves the migration
and invasion of tumor cells has been long known as a for-
midable barrier to successful treatment. Therefore, in this
present study, B1 AMCE had been put into test in vitro
assays to justify this vital feature. In the wound healing
Fig. 8 a Images of the in vitro migration analysis of 4 T1 cells; control and cells treated with IC50 value of B1 Annona muricata crude extract. The
cells were allowed to migrate through an 8 mm pore membrane for 24 h. b Quantification of migration through 8-mm pore membrane inserts
(BD Biosciences) by B1 AMCE-treated 4 T1 cells as a percentage of that achieved by control cells. The assay was done in triplicates and the data
are expressed as mean ± standard error of mean. Significance is set at *p < 0.05
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assay, B1 AMCE managed to delay the growth of 4 T1
cells towards the centre of the wound which stressed out
its propensity to prevent the migration of cancer cells.
Hepatocyte growth factor/ scatter factor (HGF/SF),
insulin-like growth factor II (IGF-II), and autotaxin which
are among several factors reported to contribute to cancer
cell motility [23] might be targeted by B1 AMCE but fur-
ther clarification is required. This anti-metastatic effect
was also well observed in the Transwell migration assay
and the invasion assay where the number of cancerous
cells was decreased in each assay in the presence of the B1
leaf extract. Evidently, this anti-metastatic potential of this
plant extract is in accord with the previous finding al-
though the setting of the study was on the pancreatic can-
cer cells [24]. Along with the in vitro studies, the in vivo
studies were also carried out. The distribution of 4 T1
breast cancer cells to the secondary site such as the lung
organ of the tumor-bearing mice was decreased in the B1
AMCE treated group as distinguished by the reduction of
colonies formed in clonogenic assay. As can be seen in
Fig. 10b, the colony formation was morphologically chan-
ged due to the B1 AMCE treatment. The formation of col-
ony from ensembles of cells could be related to cell-cell
adhesion and cell motility [25] thus, suggesting that 4 T1
cancer cells became less motile and more adhesive to each
other in the presence of B1 AMCE treatment. However, it
is noteworthy that there are no published data with
specific attention have been reported to issue pertaining
to the effect of the sample on colony size. Previous studies
has identified that metastasis of tumor is made easier by
the formation of new blood vessels at the surrounding
matrix allowing a continuous interaction with other cells
and systems of the body. As the multiple numbers of
factors are involved in angiogenesis including the likes of
growth factors, chemokines, cytokines, extracellular matrix
macromolecule, and adhesion molecule, the present study
was undertaken to observe the expression level of several
angiogenesis-related protein in B1 AMCE-treated tumor
harvested from tumor-bearing mice on the basis of the
angiogenesis proteome profiler. The findings have shown
Fig. 9 a Images of the in vitro invasion analysis of 4 T1 cells; control and cells treated with IC50 value of B1 Annona muricata crude extract. The
cells were allowed to invade through a layer of Matrigel for 24 h. b Quantification of invasion achieved by the B1 AMCE-treated 4 T1 cells as a
percentage of that achieved by control cells. The assay was done in triplicates and the data are expressed as mean ± standard error of mean.
Significance is set at *p < 0.05
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Fig. 10 a Representative images of colonies formed in lung from clonogenic assay. Dilution factor: 10-4. b Total 4 T1 colonies formed from
meshed lung harvested from the control and B1 AMCE (1 g/kg)-treated mice after 10 days of incubation. The data are expressed as means ±
standard error of the mean for triplicates. Significance is set at *p < 0.05; n = 7 mice per group
Fig. 11 Significant changes of angiogenesis-related proteins level detected by proteome profiler when treated with B1 AMCE (1 g/kg)
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that protein which includes the likes of Eotaxin, Fas lig-
and, IGF-II, IL-1β, TNF-α, IL-13, Leptin, and TIMP-1
were decreased when compared to the untreated tumor.
Eotaxin, also referred as CCL11 is a chemokine that could
foster angiogenesis through CCR3 receptor. It plays a
critical role in inflammatory reactions; allergic and non-
allergic as observed in previous studies and was also
revealed to be a direct mediator of angiogenesis given the
fact that it is an eosinophil chemoattractant which to-
gether with the eosinophilic products such as TGF-α and
–β could induce angiogenesis [26]. Moreover, the level of
Fas ligand was reduced significantly in the treated group
compared to the untreated group. Fas ligand engagement
with its receptor induces the apoptotic cell death and is
important in modulating the homeostasis of cells in the
immune system where its signal limits the expansion of T
cell clones after the elimination of antigen [27]. In certain
location of body such as the eye, testis, and placenta, Fas
ligand is found highly expressed resulting in the death of
invading Fas+ cells, including the lymphocytes which give
them a privilege from immune surveillance [28]. Such
strategy is also adopted by tumor cells to grant them an
escape pass from being targeted by immune system thus,
allowing them to successfully grow and proliferate. In
addition, the level of insulin-like growth factor-II (IGF-II)
is also dropped in the B1 AMCE-treated group. A mature
IGF-II together with its homologous polypeptide se-
quence, IGF-1 and insulin, interact with either the type-1
IGF or insulin receptor located in the plasma membrane
to transmit their growth promoting signals [29]. IGF-II
level is found elevated in breast cancer patients and its in-
volvement in cancer development could be seen through
Fig. 12 Images of tumors harvested from control and B1 AMCE (1 g/kg)-treated mice
Fig. 13 Weight of the tumors was measured after being harvested
from the mice after 28 days of treatment. The data are expressed as
means ± standard error of the mean for triplicates. n = 7 mice
per group
Fig. 14 Volume of the tumors was measured using a vernier caliper.
The data are expressed as means ± standard error of the mean for
triplicates. Significance is set at *p < 0.05; n = 7 mice per group
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Fig. 15 (See legend on next page.)
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the MAPK pathway where IGF signal activates genes con-
cerned with cell proliferation; and reduce the apoptosis
event via the PI3-K/Akt pathway, hence, the occurrence of
tumorigenesis [30]. Inflammatory cytokines such as tumor
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)
which are evidently contribute to angiogenesis, are also
decreased in the B1 AMCE-treated group. In one study,
these inflammatory cytokines alongside with inflammatory
chemokines; CCL2 and CCL5 are expressed in a coordi-
nated fashion which provides a combined role of the me-
diators to supports the growth and progression of breast
tumor [31]. Another proangiogenic cytokine, interleukin-
13 (IL-13) was also significantly less expressed in the
treated group. IL-13 which is derived from T-lymphocyte
is highly expressed in breast cancer as reported in previ-
ous studies and exerts its effect by inducing the up-
regulation of VCAM-1 which consequently modulates the
angiogenesis event [32]. Moreover, the level of tissue in-
hibitor of metalloproteinase-1 (TIMP-1), a member of the
TIMPs family, was slightly decreased in the tumor treated
group. The highly expressed TIMP-1 in breast cancer
leads to tumor growth and development plus making the
cells resistant to multiple apoptotic stimuli through the
FAK/PI-3 K/AKT survival signalling pathways [33] despite
its other role in inhibiting the MMP from degrading the
extracellular matrix as demonstrated in other findings
[34]. On the other hand, leptin which is frequently associ-
ated with obesity could also stimulate the proliferation of
breast cancer cell lines as outlined in the previous studies
[35, 36]. It is worth noting that its expression level was
significantly reduced in the B1 AMCE-treated group. In
spite of the decreased expression of several proteins, B1
AMCE could also up-regulates several proteins such as
interferon-gamma (IFN-γ) and monokine induced by
interferon-γ (Mig) which underlines its favourable criteria
as anti-cancer agent. It has been discovered that IFN-γ
has anti-tumoral effect as it manages to inhibit the growth
of tumor cell lines including breast cancer cells by causing
cell cycle arrest in the expense of p21 up-regulation as re-
ported in previous studies [37] while in another findings,
indicate that IFN-γ increases the growth inhibitory effect
of tamoxifen in breast metastatic carcinomas [38]. The
up-regulation of Mig in the treated group is a good indica-
tor for B1 AMCE as anti-angiogenesis agent due to its
ability to inhibit angiogenesis in vivo. In the presence of
Mig, the neovascularization induced by the angiogenic
factors such as IL-8, ENA-78, GCP-2, and GROα is inhib-
ited [39]. Immune responses are responsible in the eradi-
cation of the neoplastic cells via the activation of the CD4
+ and CD8+ T lymphocytes but a compromise to this bar-
rier system could cost dearly. Based on the previous find-
ings, tumor cells held its own machinery to evade from
the immune surveillance by altering the activity of the T-
cells thus, ensuring their progression [40]. From our study,
it is apparent that the percentage level of the CD4+ and
CD8+ T lymphocytes were dropped in the tumor group
when compared to the normal group. This situation could
be explained by the tumor-releasing Survivin as it has
been described in one previous study. It was shown that
Survivin, an apoptosis inhibitor, is released into extracellu-
lar space before eventually taken up by other surrounding
malignant cells which describes their aggressive phenotype
in terms of the increase of proliferative rate, resistance to-
wards therapies, and their invasive potential. Survivin is
(See figure on previous page.)
Fig. 15 a Flow cytometry analysis of immune markers (CD3, CD4, and CD8) on the splenocytes of the normal, control, and B1 AMCE (1 g/kg)-
treated mice. b Percentage of CD4/CD3 T cell population from the spleenocytes of the normal, control and B1 AMCE (1 g/ kg)-treated mice as
depicted in Fig. 15a. The data are expressed as means ± standard error of the mean for triplicates. Mean values with different superscripts are
significantly different p < 0.05; n = 7 mice per group. c Percentage of CD8/CD3 T cell population from the spleenocytes of the normal, control and
B1 AMCE (1 g/ kg)-treated mice as depicted in Fig. 15a. The data are expressed as means ± standard error of the mean for triplicates. Mean values
with different superscripts are significantly different p < 0.05; n = 7 mice per group
Fig. 16 Percentage of NK1.1/CD3+ T-cell population from spleenocytes
assay of the control and B1 AMCE (1 g/kg)-treated mice. The data are
expressed as means ± standard error of the mean for triplicates.
Significance is set at *p < 0.05; n = 7 mice per group
Table 4 Total white blood cell count in the serum harvested
from the control and B1 AMCE (1 g/kg)-treated mice
MICE Total white blood cell count, 109 /L
Control 2.4
B1 AMCE 4.5
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taken up by T-cells as well due to its binding capability
which consequently been the causal of the T-cells re-
sponse polarization where proliferation and cytotoxicity of
the T-cells are decreased [41]. Therefore, restoration of
the T-cells level back to its normal state is necessary to
combat and suppress the cancer cells. In our study, treat-
ment with B1 AMCE in the tumor-bearing mice group
marked an increase of CD4+ and CD8+ T lymphocytes
population as well as the NK1.1 level compared to the
control untreated group. Both CD8+ T-cell and NK cells
are responsible in eliminating the cancer by lysing the tu-
mors whereas T-helper cell is vital in further recruiting of
both the aforementioned lymphocytes and also the cyto-
kines for anti-tumor response purpose [42]. White blood
cells are important in fighting infection and diseases
which always appeared low in cancer patients [43] due to
cancer itself that spreads beyond bone marrow site and
displace the white blood cells or from the chemotherapy
session. The increase in total white blood cell count may
suggest the potential of B1 AMCE as a cancer therapy in
recovering the white blood cell loss. Inflammation which
is often related to immune modulatory response could ini-
tiate the progression of cancer once become chronic. One
of the main culprits linking to this association is nitric
oxide, a free radical product of NO synthase (NOS) where
it is highly expressed in cancer cells and accounts for
other multiple reactive intermediates [44]. Persistent ex-
pression of this mutagenic NO could contribute to tumor
growth, metastasis, and angiogenesis as indicated in previ-
ous studies [45, 46]. Interestingly, B1 AMCE treatment ex-
hibits a good therapeutic profile with a marked decrease
of NO level within the tumor. Additionally, lipid peroxida-
tion of polyunsaturated fatty acids is also induced in the
wake of inflammatory response where it gives rise to
several secondary products including malondialdehye
(MDA), a highly toxic molecule [47, 48]. An intervention
of the production of MDA is necessary to inhibit DNA
damage and also to treat cancer, in overall perspective
[49]. It is apparent that B1 AMCE could decrease the level
of MDA within the tumor when compared to the un-
treated group thereby supporting the therapeutic potential
of this leaf crude extract.
Conclusion
Based on the results obtained from this study, it is im-
perative to carefully select the soursop samples from its
cultivation area as it could determine the potency and
anticancer activity of certain soursop sample. B1 AMCE
has a good profile to be a candidate for breast cancer
treatment as it managed to induce the apoptosis of 4 T1
breast cancer cells, inhibited the metastasis in vitro and
in vivo, regulated the immune system, and reduced the
inflammation caused by cancer. Nevertheless, a further
evaluation of AMCE is needed to gain knowledge about
its anticancer activity and mechanism.
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